Takuma Tsuchida1, Youngmin A Lee2, Naoto Fujiwara2, Maria Ybanez2, Brittany Allen2, Sebastiao Martins3, M Isabel Fiel4, Nicolas Goossens2, Hsin-I Chou2, Yujin Hoshida2, Scott L Friedman5. 1. Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Research Division, Mitsubishi Tanabe Pharma Corporation, Saitama, Japan. 2. Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. 3. Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Departamento de Patologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, Brazil. 4. Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA. 5. Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA. Electronic address: Scott.Friedman@mssm.edu.
Abstract
BACKGROUND AND AIMS: Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24-52 weeks, which makes testing for drug response costly and time consuming. METHODS: We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl4), which serves as an accelerator. RESULTS: C57BL/6J mice were fed a normal chow diet ± CCl4 or WD ± CCl4 for 12 and 24 weeks. Addition of CCl4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl4 mice and immunologic features were similar to those of human NASH. CONCLUSIONS: Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. LAY SUMMARY: A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
BACKGROUND AND AIMS: Although the majority of patients with non-alcoholic fatty liver disease (NAFLD) have only steatosis without progression, a sizeable fraction develop non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and hepatocellular carcinoma (HCC). Many established diet-induced mouse models for NASH require 24-52 weeks, which makes testing for drug response costly and time consuming. METHODS: We have sought to establish a murine NASH model with rapid progression of extensive fibrosis and HCC by using a western diet (WD), which is high-fat, high-fructose and high-cholesterol, combined with low weekly dose of intraperitoneal carbon tetrachloride (CCl4), which serves as an accelerator. RESULTS: C57BL/6J mice were fed a normal chow diet ± CCl4 or WD ± CCl4 for 12 and 24 weeks. Addition of CCl4 exacerbated histological features of NASH, fibrosis, and tumor development induced by WD, which resulted in stage 3 fibrosis at 12 weeks and HCC development at 24 weeks. Furthermore, whole liver transcriptomic analysis indicated that dysregulated molecular pathways in WD/CCl4 mice and immunologic features were similar to those of human NASH. CONCLUSIONS: Our mouse NASH model exhibits rapid progression of advanced fibrosis and HCC, and mimics histological, immunological and transcriptomic features of human NASH, suggesting that it will be a useful experimental tool for preclinical drug testing. LAY SUMMARY: A carefully characterized model has been developed in mice that recapitulates the progressive stages of human fatty liver disease, from simple steatosis, to inflammation, fibrosis and cancer. The functional pathways of gene expression and immune abnormalities in this model closely resemble human disease. The ease and reproducibility of this model make it ideal to study disease pathogenesis and test new treatments.
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Jae-Seong Yang; Jin Taek Kim; Jouhyun Jeon; Ho Sun Park; Gyeong Hoon Kang; Kyong Soo Park; Hong Kyu Lee; Sanguk Kim; Young Min Cho Journal: PLoS One Date: 2010-11-05 Impact factor: 3.240
Authors: Seong Chul Kim; Chun-Ki Kim; David Axe; Aaron Cook; Mikang Lee; Tiangang Li; Nicole Smallwood; John Y L Chiang; James P Hardwick; David D Moore; Yoon Kwang Lee Journal: Hepatology Date: 2014-03-26 Impact factor: 17.425
Authors: Joanna K Dowman; Laurence J Hopkins; Gary M Reynolds; Nikolaos Nikolaou; Matthew J Armstrong; Jean C Shaw; Diarmaid D Houlihan; Patricia F Lalor; Jeremy W Tomlinson; Stefan G Hübscher; Philip N Newsome Journal: Am J Pathol Date: 2014-03-17 Impact factor: 4.307
Authors: Chi Ma; Aparna H Kesarwala; Tobias Eggert; José Medina-Echeverz; David E Kleiner; Ping Jin; David F Stroncek; Masaki Terabe; Veena Kapoor; Mei ElGindi; Miaojun Han; Angela M Thornton; Haibo Zhang; Michèle Egger; Ji Luo; Dean W Felsher; Daniel W McVicar; Achim Weber; Mathias Heikenwalder; Tim F Greten Journal: Nature Date: 2016-03-02 Impact factor: 49.962
Authors: Barbara Borowa-Mazgaj; Aline de Conti; Volodymyr Tryndyak; Colleen R Steward; Leandro Jimenez; Stepan Melnyk; Mulugeta Seneshaw; Faridodin Mirshahi; Ivan Rusyn; Frederick A Beland; Arun J Sanyal; Igor P Pogribny Journal: Toxicol Sci Date: 2019-08-01 Impact factor: 4.849
Authors: Mark A Febbraio; Saskia Reibe; Shabnam Shalapour; Geraldine J Ooi; Matthew J Watt; Michael Karin Journal: Cell Metab Date: 2018-11-15 Impact factor: 27.287